Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Related Keywords

Sandip Patel ,Tina Cascone , ,Recent Updates ,Translating Evidence ,Clinical Practice ,Patients Unsuitable ,Eben Levy ,Nsclc ,Early Nsclc ,Non Small Cell Lung Cancer ,Asco 2023 ,Localized Disease ,Presection ,Surgery ,Staging ,Chemoimmunotherapy ,Immunotherapy ,Ohio ,Molecular Testing ,Liquid Biopsy ,Tissue Biopsy ,Ngs Testing ,Egfr ,Talk ,